| Title: |
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies |
| Authors: |
Domingo, Enric; Kelly, Caroline; Hay, Jennifer; Sansom, Owen; Maka, Noori; Oien, Karin; Iveson, Tim; Saunders, Mark; Kerr, Rachel; Tomlinson, Ian; Edwards, Joanne; Harkin, Andrea; Nowak, Marta; Koelzer, Viktor; Easton, Alistair; Boukovinas, Ioannis; Moustou, Eleni; Messaritakis, Ippokratis; Chondrozoumaki, Maria; Karagianni, Michaela; Pagès, Franck; Arnoux, Fanny; Lautard, Christelle; Lovera, Yoann; Boquet, Isabelle; Catteau, Aurélie; Galon, Jérôme; TransSCOT Consortium; Souglakos, Ioannis; Church, David N |
| Source: |
Domingo, Enric; Kelly, Caroline; Hay, Jennifer; Sansom, Owen; Maka, Noori; Oien, Karin; Iveson, Tim; Saunders, Mark; Kerr, Rachel; Tomlinson, Ian; Edwards, Joanne; Harkin, Andrea; Nowak, Marta; Koelzer, Viktor; Easton, Alistair; Boukovinas, Ioannis; Moustou, Eleni; Messaritakis, Ippokratis; Chondrozoumaki, Maria; Karagianni, Michaela; Pagès, Franck; Arnoux, Fanny; Lautard, Christelle; Lovera, Yoann; Boquet, Isabelle; Catteau, Aurélie; Galon, Jérôme; TransSCOT Consortium; Souglakos, Ioannis; Church, David N (2024). Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies. Journal of Clinical Oncology, 42(18):2207-2218. |
| Publisher Information: |
American Society of Clinical Oncology |
| Publication Year: |
2024 |
| Collection: |
University of Zurich (UZH): ZORA (Zurich Open Repository and Archive |
| Subject Terms: |
Institute of Pathology and Molecular Pathology; 610 Medicine & health |
| Description: |
PURPOSE Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 v 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We sought to determine IS prognostic and predictive value in stage-III CRC treated with adjuvant FOLFOX or oral capecitabine and infusional oxaliplatin (CAPOX) in the SCOT and IDEA-HORG trials. METHODS Three thousand sixty-one cases had tumor samples, of which 2,643 (1,792 CAPOX) were eligible for IS testing. Predefined cutoffs (IS-Low and IS-High) were used to classify cases into two groups for analysis of disease-free survival (3-year DFS) and multivariable-adjusted hazard ratios (mvHRs) by Cox regression. RESULTS IS was determined in 2,608 (99.5%) eligible cases, with 877 (33.7%) samples classified as IS-Low. IS-Low tumors were more commonly high-risk (T4 and/or N2; 52.9% IS-Low v 42.2% IS-High; P < .001) and in younger patients (P=.024). Patients with IS-Low tumors had significantly shorter DFS in the CAPOX, FOLFOX, and combined cohorts (mvHR, 1.52 [95% CI, 1.28 to 1.82]; mvHR, 1.58 [95% CI, 1.22 to 2.04]; and mvHR, 1.55 [95% CI, 1.34 to 1.79], respectively; P < .001 all comparisons), regardless of sex, BMI, clinical risk group, tumor location, treatment duration, or chemotherapy regimen. IS prognostic value was greater in younger (≤65 years) than older (>65 years) patients in the CAPOX cohort (mvHR, 1.92 [95% CI, 1.50 to 2.46] v 1.28 [95% CI, 1.01 to 1.63], P$_{INTERACTION}$ = .026), and in DNA mismatch repair proficient than deficient mismatch repair disease (mvHR, 1.68 [95% CI, 1.41 to 2.00] v 0.67 [95% CI, 0.30 to 1.49], P$_{INTERACTION}$ = .03), although these exploratory analyses were uncorrected for multiple testing. Adding IS to a model containing all clinical variables significantly improved prediction of DFS (likelihood ratio test, P < .001) regardless of MMR status. CONCLUSION IS is prognostic in stage III CRC treated with FOLFOX or CAPOX, including within clinically ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
0732-183X |
| Relation: |
https://www.zora.uzh.ch/id/eprint/266252/1/Domingo_GastCanc_2024.pdf; info:pmid/38484206; urn:issn:0732-183X |
| DOI: |
10.1200/JCO.23.01648 |
| Availability: |
https://www.zora.uzh.ch/id/eprint/266252/; https://www.zora.uzh.ch/id/eprint/266252/1/Domingo_GastCanc_2024.pdf; https://doi.org/10.1200/JCO.23.01648 |
| Rights: |
info:eu-repo/semantics/openAccess ; Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ; http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.469B2DC1 |
| Database: |
BASE |